<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002831</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH CIK02</org_study_id>
    <nct_id>NCT03002831</nct_id>
  </id_info>
  <brief_title>Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer</brief_title>
  <official_title>Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer: A Prospective, Randomized, Open, Single Center Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Cytokine induced killer cells combined
      chemotherapy is more effective in the treatment of advanced Pancreatic Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is a devastating malignant disease with a median survival of 3-6 months and
      a 5-year survival rate of less than 5%. It is necessary to explore more treatment mode to
      pancreatic cancer especially advanced stage patients. This study is a prospective,
      randomized, open, single center phase II study. The investigators try to evaluate the
      efficacy and safety of this treatment mode.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of randomization to the date of death from any cause up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From the date of randomization to the date of first documented progression up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Questionnaire</measure>
    <time_frame>one year by questionnaire</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>CIK combined chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine-induced Killer Cells</intervention_name>
    <arm_group_label>CIK combined chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-Gimeracil-Oteracil Potassium</intervention_name>
    <arm_group_label>CIK combined chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No less than 18 years old

          2. Karnofsky Performance Status over 60

          3. Life expectancy more than three months

          4. Pathological diagnosed as pancreatic epithelial cell carcinoma

          5. Recurrence after surgery or unresectable

          6. No experienced chemotherapy or the interval between the last adjuvant chemotherapy and
             relapse is at least 6 months

          7. Measurable lesions (by CT or MRI)

          8. No serious mental disorders

          9. Adequate organ and bone marrow functions

         10. No other serious and the conflict diseases(such as autoimmune diseases,
             immunodeficiency, organ transplantation)

         11. No other malignant tumor history

         12. Informed consent and willing to participate in this study

        Exclusion Criteria:

          1. Received immunosuppressants or glucocorticoid treatment

          2. Uncontrolled severe infection or unhealed wound caused by suppurative inflammation

          3. Heart disease, insufficient heart function, II degree heart block or occurred
             myocardial infarction in 6 months

          4. Poor pulmonary functions caused by interstitial lung disease and pulmonary reserve
             volume under 80% of the expected value

          5. Other malignant tumor history

          6. Transaminase&gt;2.5ULN or bilirubin&gt;3ULN or creatinine &gt;1.25ULN

          7. Pregnant or lactating women

          8. Obvious bleeding tendency

          9. Participated other clinical trails in 1 month

         10. Other unsuitable conditions: HIV infection, intravenous drug abusers, etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quanli Gao, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanli Gao, Ph.D.</last_name>
    <phone>+86-371 65587795</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaomin Fu, M.D.</last_name>
    <phone>+86-371 65588219</phone>
    <email>fuxiaomin0880@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanli Gao, M.D</last_name>
      <phone>+86-371-65587795</phone>
      <email>gaoquanli2015@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaomin Fu, M.D.</last_name>
      <phone>+86-371-65587098</phone>
      <email>fuxiaomin0880@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno N, Hijioka S, Hara K, Yazumi S, Shimizu Y, Yamao K. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. Eur J Cancer. 2016 Feb;54:96-103. doi: 10.1016/j.ejca.2015.11.002. Epub 2015 Dec 30.</citation>
    <PMID>26741729</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang Z, Liu Y, Li R, Shang Y, Zhang Y, Zhao L, Li W, Yang Y, Zhang X, Yang T, Nie C, Han F, Liu Y, Luo S, Gao Q, Song Y. Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. J Hematol Oncol. 2016 Feb 3;9:6. doi: 10.1186/s13045-016-0237-6.</citation>
    <PMID>26842696</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CIK</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

